Loading...
Market
Company with highest market share in hypoparathyroidism treatments by end of 2024?
2
Resolution / Starting Odds
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Market share reports from industry analysts or financial news outlets
Story
FDA Approves Ascendis Pharma's YORVIPATH for Hypoparathyroidism; Stock Rises 10% Post-Takeda
Aug 12, 2024, 11:40 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide), marking it as the first and only treatment for hypoparathyroidism in adults. This approval positions YORVIPATH as the sole available treatment for this rare hormone disorder in the United States, following the discontinuation of Takeda's previous therapy. The announcement led to a 10% increase in Ascendis Pharma's stock price in premarket trading.
View original story
Similar markets
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Avadel Pharmaceuticals • 25%
Jazz Pharmaceuticals • 25%
Another Company • 25%
No Dominant Player • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Takeda Pharmaceutical • 25%
Teva Pharmaceutical • 25%
Eli Lilly • 25%
Other • 25%
Less than 20% market share • 33%
20%-40% market share • 34%
More than 40% market share • 33%